资讯

The Manila Times32 分钟

FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First Non-Invasive ...

This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development ...